SCHEMBL3017934

SCHEMBL3017934

COc1ccc(OC)c(Cc2csc(N3CCN(S(=O)(=O)c4cccc(F)c4)CC3)n2)c1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.54
RECQL P46063 2/20 0.54
USP2 O75604 2/20 0.54
HSD17B10 Q99714 1/20 0.54
MEN1 O00255 1/20 0.52
GFER P55789 1/20 0.52
KMT2A Q03164 1/20 0.52
TP53 P04637 1/20 0.48
SMN1; SMN2 Q16637 2/20 0.46
TSHR P16473 2/20 0.45
LMNA P02545 2/20 0.45
MAPK1 P28482 1/20 0.45
ALDH1A1 P00352 4/20 0.43
THRB P10828 1/20 0.42
L3MBTL1 Q9Y468 3/20 0.42
IDO1 P14902 1/20 0.42
POLB P06746 3/20 0.42
HTT P42858 2/20 0.42
PKM P14618 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3012668 0.93 MAPT (0.54) MAPTRECQLUSP2HSD17B10MEN1
SCHEMBL3017481 0.91 MAPT (0.61) MAPTRECQLUSP2HSD17B10KMT2A
SCHEMBL3017596 0.91 GFER (0.59) MAPTRECQLUSP2HSD17B10MEN1
SCHEMBL3012533 0.90 TP53 (0.48) MAPTRECQLUSP2HSD17B10MEN1
SCHEMBL3005437 0.90 TP53 (0.48) MAPTRECQLUSP2HSD17B10KMT2A
SCHEMBL3002769 0.89 L3MBTL1 (0.49) MAPTRECQLUSP2HSD17B10MEN1
SCHEMBL3008856 0.89 TSHR (0.50) MAPTRECQLUSP2HSD17B10TP53
SCHEMBL3002772 0.88 MAPT (0.49) MAPTRECQLUSP2HSD17B10KMT2A
SCHEMBL3017125 0.88 MAPT (0.55) MAPTRECQLUSP2HSD17B10MEN1
SCHEMBL3007163 0.87 MAPT (0.49) MAPTRECQLUSP2HSD17B10MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885RECQL 1564/4885USP2 1831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.